Lyell Immunopharma, Inc.
LYEL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | -0.08 | 0.17 | -0.34 |
| FCF Yield | -97.32% | -34.17% | -22.61% | -10.21% |
| EV / EBITDA | -0.60 | -1.78 | -4.74 | -8.22 |
| Quality | ||||
| ROIC | -80.61% | -34.22% | -20.67% | -19.85% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.47 | 0.70 | 0.93 | 0.50 |
| Growth | ||||
| Revenue 3-Year CAGR | -91.04% | -76.98% | 121.85% | 153.08% |
| Free Cash Flow Growth | 2.12% | 14.16% | -1.08% | 9.70% |
| Safety | ||||
| Net Debt / EBITDA | 0.23 | 0.36 | 0.33 | 1.12 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |